MOTO - T Cell kurapwa, CAR T Therapy, MOTO T-Cell, chimeric agent
Dive Yakadzika muCAR T Cell Therapy: Inoshanda Sei?
Ziva sainzi kuseri kweCAR T Cell kurapwa muIndia! Ongorora kuti iyi shanduko yekurapa inoshandura sei maseru edziviriro yako kuita cancer fighters. Verenga blog yedu izvozvi kuti udzidze zvakawanda nezve ichi chishamiso kurapa uye sei ..
MOTO T-Cell, CAR kurapwa, immunotherapy, T cell kurapa
Ko CAR T-Cell Therapy Inowanikwa muIndia?
Wakambozvibvunza here kana paine nzira ine simba yekurwisa cancer? Zvino chimbofungidzira kana rimwe zuva ukawana rayi retariro mukurwira kwako gomarara, kurapwa kunoshandisa simba remuviri wako wega immune system kunanga ..
IDH1 kuchinja, olutasidenib, refractory acute myeloid leukemia, Rezlidhia
Olutasidenib inotenderwa neFDA yekudzokazve kana refractory acute myeloid leukemia ine inotapukira IDH1 mutation.
Zvita 2022: Olutasidenib (Rezlidhia) macapsules akabvumidzwa neFood and Drug Administration (FDA) yevarwere vakuru vane acute myeloid leukemia (AML) inotapukira IDH1 inotapukira.
Asparaginase erwinia chrysanthemi, Jazz Mishonga, Rylaze
New dosing regimen ye asparaginase erwinia chrysanthemi (recombinant) inotenderwa neFDA.
Zvita 2022: Iyo nyowani Muvhuro-Chitatu-Chishanu dosing chirongwa cheasparaginase erwinia chrysanthemi (recombinant) -rywn yakabvumidzwa neChikafu uye Drug Administration (Rylaze, Jazz Pharmaceuticals). Varwere vanofanira kugamuchira 25 mg/m.
ivosidenib, NCT03173248, Servier Pharmaceuticals LLC, Tibsovo
Ivosidenib pamwe chete neazacitidine inotenderwa ichangobva kuongororwa acute myeloid leukemia
Chikumi 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) pamwe neazacitidine yakatenderwa neFood and Drug Administration ichangobva kuwanikwa acute myeloid leukemia (AML) muvanhu vakuru vane makore makumi manomwe nemashanu kana kupfuura.
AZA-JMML-001, Nhoroondo ye Celgene Corporation, vechidiki myelomonocytic leukemia, NCT02447666, Vidaza
Azacitidine inotenderwa neFDA kune ichangobva kuongororwa pwere myelomonocytic leukemia
Chikumi 2022: FDA yakabvumidza mushonga weazacitidine (Vidaza, Celgene Corp.) wevana vachangobva kubatwa nejuvenile myelomonocytic leukemia (JMML). The pharmacokinetics, pharmacodynamics, chengetedzo, uye chiitiko che azacitidine p.
uduku leukemia, Chronic leukemias, induction chemotherapy, Leukemia, vana leukemia
Childhood leukemia uye kurapwa kwayo
Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Chronic leu..
Burkitt lymphoma, Burkitt-kufanana lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab pamwe nechemotherapy inotenderwa neFDA kune zviratidzo zvegomarara revana
Kurume 2022: Chikafu neDrug Administration yakabvumidza rituximab (Rituxan, Genentech, Inc.) pamwe chete nechemotherapy yeCD20-positive diffuse hombe B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
Asciminib, chisingaperi myeloid leukemia, Novartis AG, Ph+ CML, Philadelphia chromosome, Scemblix
Asciminib inotenderwa kuPhiladelphia chromosome-positive chronic myeloid leukemia
Mbudzi 2021: Asciminib (Scemblix, Novartis AG) yakapihwa yakakurumidza kubvumidzwa neFood and Drug Administration kune varwere vane Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) muchikamu chisingaperi (CP) vaive nepr.
bhora, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel inotenderwa neFDA kuti idzoke kana refractory B-cell precursor acute lymphoblastic leukemia.
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). In..